Xu, Qin, Sharif, Maria, James, Edward, Dismorr, Jack O., Tucker, James H. R., Willcox, Benjamin E. and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2024. Phosphonodiamidate prodrugs of phosphoantigens (ProPAgens) exhibit potent Vγ9/Vδ2 T cell activation and eradication of cancer cells †. RSC Medicinal Chemistry 15 (7) , pp. 2462-2473. 10.1039/d4md00208c |
Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2023. Parkinson's disease: are PINK1 activators inching closer to the clinic? ACS Medicinal Chemistry Letters 14 (7) , pp. 870-874. 10.1021/acsmedchemlett.3c00070 |
Lambourne, Olivia A., Bell, Shane, Wilhelm, Léa P., Yarbrough, Erika B., Holly, Gabriel G., Russell, Oliver M., Alghamdi, Arwa M., Fdel, Azeza M., Varricchio, Carmine ORCID: https://orcid.org/0000-0002-1673-4768, Lane, Emma L. ORCID: https://orcid.org/0000-0001-8800-3764, Ganley, Ian G., Jones, Arwyn T. ORCID: https://orcid.org/0000-0003-2781-8905, Goldberg, Matthew S. and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2023. PINK1-Dependent mitophagy inhibits elevated ubiquitin phosphorylation caused by mitochondrial damage. Journal of Medicinal Chemistry 66 (11) , pp. 7645-7656. 10.1021/acs.jmedchem.3c00555 |
Elvers, Karen T., Lipka-Lloyd, Magdalena, Trueman, Rebecca C., Bax, Benjamin D. ORCID: https://orcid.org/0000-0003-1940-3785 and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2022. Structures of the human SPAK and OSR1 conserved C-terminal (CCT) domains. ChemBioChem 23 (1) , e202100441. 10.1002/cbic.202100441 |
Alanazi, Ashwag S., Miccoli, Ageo and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2021. Aryloxy pivaloyloxymethyl prodrugs as nucleoside monophosphate prodrugs. Journal of Medicinal Chemistry 64 (22) , 16703–16710. 10.1021/acs.jmedchem.1c01490 |
Xu, Qin, Taher, Taher E., Ashby, Elizabeth, Sharif, Maria, Willcox, Benjamin E. and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2021. Generation of stable isopentenyl monophosphate aryloxy triester phosphoramidates as activators of Vγ9Vδ2 T cells. ChemMedChem 16 (15) , pp. 2375-2380. 10.1002/cmdc.202100198 |
Elzwawi, Abdulrahman, Grafton, Gillian, Barnes, Nicholas M. and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2020. SPAK and OSR1 kinases bind and phosphorylate the β2-Adrenergic receptor. Biochemical and Biophysical Research Communications 532 (1) , pp. 88-93. 10.1016/j.bbrc.2020.07.143 |
Kadri, Hachemi, Taher, Taher E., Xu, Qin, Sharif, Maria, Ashby, Elizabeth, Bryan, Richard T., Willcox, Benjamin E. and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2020. Aryloxy diester phosphonamidate prodrugs of phosphoantigens (ProPAgens) as potent activators of Vγ9/Vδ2 T-Cell immune responses. Journal of Medicinal Chemistry 63 (19) , pp. 11258-11270. 10.1021/acs.jmedchem.0c01232 |
Miccoli, Ageo, Dhiani, Binar A., Thornton, Peter J., Lambourne, Olivia A., James, Edward, Kadri, Hachemi and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2020. Aryloxy triester phosphoramidates as phosphoserine prodrugs: a proof of concept study. ChemMedChem 15 (8) , pp. 671-674. 10.1002/cmdc.202000034 |
Dhiani, Binar Asrining and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2020. The Cul4‐DDB1‐WDR3/WDR6 complex binds SPAK and OSR1 kinases in a phosphorylation‐dependent manner. ChemBioChem 21 (5) , pp. 638-643. 10.1002/cbic.201900454 |
AlAmri, Mubarak A., Jeeves, Mark and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2019. Sequence specific assignment and determination of OSR1 C-terminal domain structure by NMR. Biochemical and Biophysical Research Communications 512 (2) , pp. 338-343. 10.1016/j.bbrc.2019.03.065 |
Miccoli, Ageo, Dhiani, Binar and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2019. Phosphotyrosine prodrugs: design, synthesis and anti-STAT3 activity of ISS-610 aryloxy triester phosphoramidate prodrugs. MedChemComm 10 (2) , pp. 200-208. 10.1039/C8MD00244D |
Alanazi, Ashwag S., James, Edward and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2019. The protide prodrug technology: Where next? ACS Medicinal Chemistry Letters 10 (1) , pp. 2-5. 10.1021/acsmedchemlett.8b00586 |
Lambourne, Olivia A. and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2018. Chemical strategies for activating PINK1, a protein kinase mutated in Parkinson's Disease. ChemBioChem 19 (23) , pp. 2433-2437. 10.1002/cbic.201800497 |
AlAmri, Mubarak A, Kadri, Hachemi, Jeeves, Mark, Alderwick, Luke J and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2018. The photosensitizing clinical agent verteporfin is an inhibitor of SPAK and OSR1 kinases. ChemBioChem 19 (19) , pp. 2072-2080. 10.1002/cbic.201800272 |
Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513, Alamri, Mubarak A., Dhiani, Binar A. and Kadri, Hachemi 2018. C -terminal phosphorylation of SPAK and OSR1 kinases promotes their binding and activation by the scaffolding protein MO25. Biochemical and Biophysical Research Communications 503 (3) , pp. 1868-1873. 10.1016/j.bbrc.2018.07.128 |
Kadri, Hachemi, Lambourne, Olivia A and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2018. Niclosamide, a drug with many (re)purposes. ChemMedChem 13 (11) , pp. 1088-1091. 10.1002/cmdc.201800100 |
Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513, Rattan, Hardeep S. and Balzarini, Jan 2018. The ProTide prodrug technology: from the concept to the clinic. Journal of Medicinal Chemistry 61 (6) , pp. 2211-2226. 10.1021/acs.jmedchem.7b00734 |
Davey, Martin S., Malde, Roshni, Mykura, Rory C., Baker, Alfie T., Taher, Taher E., Le Duff, Cécile S., Willcox, Benjamin E. and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2018. Synthesis and biological evaluation of (E)-4-hydroxy-3-methylbut2-enyl phosphate (HMBP) aryloxy triester phosphoramidate Prdrugs as activators of Vγ9/Vδ2 T-cells immune response. Journal of Medicinal Chemistry 61 (5) , pp. 2111-2117. 10.1021/acs.jmedchem.7b01824 |
Barini, Erica, Miccoli, Ageo, Tinarelli, Federico, Mulholand, Katie, Kadri, Hachemi, Khanim, Farhat, Stojanovski, Laste, Read, Kevin D, Burness, Kerry, Blow, Julian J, Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 and Muqit, Miratul 2018. The anthelmintic drug niclosamide and its analogues activate the Parkinson's Disease associated protein kinase PINK1. Chembiochem 19 (5) , pp. 425-429. 10.1002/cbic.201700500 |
Salim, Mahboob, Knowles, Timothy J., Baker, Alfie T., Davey, Martin S., Jeeves, Mark, Sridhar, Pooja, Wilkie, John, Willcox, Carrie R., Kadri, Hachemi, Taher, Taher E, Vantourout, Pierre, Hayday, Adrian, Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513, Mohammed, Fiyaz and Willcox, Benjamin E. 2017. BTN3A1 discriminates γδ T cell phosphoantigens from non-antigenic small molecules via a conformational sensor in its B30.2 domain. ACS Chemical Biology 12 (10) , pp. 2631-2643. 10.1021/acschembio.7b00694 |
AlAmri, Mubarak A., Kadri, Hachemi, Dhiani, Binar Asrining, Mahmood, Shumail, Elzwawi, Abdulrahman and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2017. WNK-signaling inhibitors as potential new antihypertensive drugs. Chemmedchem 10.1002/cmdc.201700425 |
Alamri, Mubarak A., Kadri, Hachemi, Alderwick, Luke J., Simpkins, Nigel S. and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2017. Rafoxanide and Closantel inhibit SPAK and OSR1 kinases by binding to a highly conserved allosteric site on their C-terminal domains. ChemMedChem 12 (9) , pp. 639-645. 10.1002/cmdc.201700077 |
Osgerby, Laura, Lai, Yu-Chiang, Thornton, Peter J., Amalfitano, Joseph, Le Duff, Cécile S., Jabeen, Iqra, Kadri, Hachemi, Miccoli, Ageo, Tucker, James H. R., Muqit, Miratul M. K. and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2017. Kinetin riboside and its ProTides activate the Parkinson's Disease associated PTEN-Induced Putative Kinase 1 (PINK1) independent of mitochondrial depolarization. Journal of Medicinal Chemistry 60 (8) , pp. 3518-3524. 10.1021/acs.jmedchem.6b01897 |
Kadri, Hachemi, Alamri, Mubarak A., Navratilova, Iva H., Alderwick, Luke J., Simpkins, Nigel S. and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2017. Towards the development of small molecule MO25-binders as potential indirect SPAK/OSR1 kinase inhibitors. ChemBioChem 18 (5) , pp. 460-465. 10.1002/cbic.201600620 |
Kedge, Jonathan L., Nguyen, Huy V., Khan, Zahra, Male, Louise, Hodges, Media K. Ismail Holly V. Roberts Ni, Horswell, Sarah L., Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 and Tucker, James H. R. 2017. Organometallic nucleoside analogues: effect of hydroxyalkyl linker length on cancer cell line toxicity. European Journal of Inorganic Chemistry 2017 (2) , pp. 466-476. 10.1002/ejic.201600853 |
Thornton, Peter J., Kadri, Hachemi, Miccoli, Ageo and Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2016. Nucleoside phosphate and phosphonate prodrug clinical candidates. Journal of Medicinal Chemistry 59 (23) , pp. 10400-10410. 10.1021/acs.jmedchem.6b00523 |
Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2016. The ProTides boom. Chemmedchem 11 (11) , pp. 1114-1116. 10.1002/cmdc.201600156 |
Nguyen, Huy V., Sallustrau, Antoine, Balzarini, Jan, Bedford, Matthew R., Eden, John C., Georgousi, Niki, Hodges, Nikolas J., Kedge, Jonathan, Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513, Tselepis, Chris and Tucker, James H. R. 2014. Organometallic nucleoside analogues with ferrocenyl linker groups: Synthesis and cancer cell line studies. Journal of Medicinal Chemistry 57 (13) , pp. 5817-5822. 10.1021/jm500246h |
Ohta, Akihito, Schumacher, Frances-Rose, Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513, Johnson, Clare, Knebel, Axel, Macartney, Thomas J., Wood, Nicola T., Alessi, Dario R. and Kurz, Thimo 2013. The CUL3–KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction. Biochemical Journal 451 (1) , pp. 111-122. 10.1042/BJ20121903 |
Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513, Alessi, Dario R., Macartney, Thomas J., Szklarz, Marta, Knapp, Stefan and Elkins, Jonathan M. 2013. Structural insights into the activation of MST3 by MO25. Biochemical and Biophysical Research Communications 431 (3) , pp. 604-609. 10.1016/j.bbrc.2012.12.113 |
Chen, Shengxi, Fahmi, Nour Eddine, Nangreave, Ryan C., Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 and Hecht, Sidney M. 2012. Synthesis of pdCpAs and transfer RNAs activated with thiothreonine and derivatives. Bioorganic & Medicinal Chemistry 20 (8) , pp. 2679-2689. 10.1016/j.bmc.2012.02.024 |
Thastrup, Jacob O., Rafiqi, Fatema H., Vitari, Alberto C., Pozo-Guisado, Eulalia, Deak, Maria, Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 and Alessi, Dario R. 2012. SPAK/OSR1 regulate NKCC1 and WNK activity: analysis of WNK isoform interactions and activation by T-loop trans-autophosphorylation. Biochemical Journal 441 (1) , pp. 325-337. 10.1042/BJ20111879 |
Filippi, Beatrice M., de los Heros, Paola, Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513, Navratilova, Iva, Gourlay, Robert, Deak, Maria, Plater, Lorna, Toth, Rachel, Zeqiraj, Elton and Alessi, Dario R. 2011. MO25 is a master regulator of SPAK/OSR1 and MST3/MST4/YSK1 protein kinases. EMBO Journal 30 (9) , pp. 1730-1741. 10.1038/emboj.2011.78 |
Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 2010. Phosphoramidate Prodrugs Deliver with Potency Against Hepatitis C Virus. ChemMedChem 5 (11) , pp. 1841-1842. 10.1002/cmdc.201000310 |
Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513, Valente, Rocco, Mottram, Huw James, Walsby, Elisabeth Jane ORCID: https://orcid.org/0000-0001-8523-5017, Mills, Kenneth Ian, Balzarini, Jan and McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X 2010. Phosphoramidates of 2′-β-d-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. Bioorganic & Medicinal Chemistry 18 (7) , pp. 2439-2446. 10.1016/j.bmc.2010.02.059 |
Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513, Balzarini, Jan and McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X 2010. The design, synthesis and antiviral evaluation of a series of 5-trimethylsilyl-1-β-D-(arabinofuranosyl)uracil phosphoramidate ProTides. Antiviral Chemistry & Chemotherapy 20 (4) , pp. 153-160. 10.3851/IMP1476 |
Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513 and De Clercq, Erik 2010. Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go? Journal of Medicinal Chemistry 53 (2) , pp. 521-538. 10.1021/jm900492g |
Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513, Balzarini, J. and McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X 2009. An investigation into the anti-HIV activity of 2 ',3 '-didehydro-2 ',3 '-dideoxyuridine (d4U) and 2 ',3 '-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives. Organic and Biomolecular Chemistry 7 (12) , pp. 2548-2553. 10.1039/b904276h |
Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513, Balzarini, J. and McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X 2009. Aryloxy Phosphoramidate Triesters: a Technology for Delivering Monophosphorylated Nucleosides and Sugars into Cells. Chemmedchem 4 (11) , pp. 1779-1791. 10.1002/cmdc.200900289 |
Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513, McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X, Brancale, Andrea ORCID: https://orcid.org/0000-0002-9728-3419 and Balzarini, J. 2007. Design, synthesis, and anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U), 2',3'-dideoxyuridine (ddU) phosphoramidate "ProTide' derivatives. Biorganic and Medicinal Chemistry Letters 17 (13) , pp. 3666-3669. 10.1016/j.bmcl.2007.04.043 |
Mehellou, Youcef ORCID: https://orcid.org/0000-0001-5720-8513, McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X and Balzarini, J. 2007. The design, synthesis and Anti-HIV activity of a selected group of 2 ',3 '-didehydro-2 ',3 '-dideoxyguanosine (d4G) and 2 ',3 '-dideoxyguanosine (ddG) 'ProTide' derivatives. Antiviral Research 74 (3) , 50. 10.1016/j.antiviral.2007.01.063 |